- Home
- BOSC vs NXTC Comparison
BOSC vs NXTC Comparison
Compare BOSC & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOSC
- NXTC
- Stock Information
- Founded
- BOSC 1990
- NXTC 2015
- Country
- BOSC Israel
- NXTC United States
- Employees
- BOSC N/A
- NXTC N/A
- Industry
- BOSC Computer Communications Equipment
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- BOSC Telecommunications
- NXTC Health Care
- Exchange
- BOSC Nasdaq
- NXTC Nasdaq
- Market Cap
- BOSC 29.6M
- NXTC 24.6M
- IPO Year
- BOSC 1996
- NXTC 2019
- Fundamental
- Price
- BOSC $5.61
- NXTC $10.35
- Analyst Decision
- BOSC
- NXTC Strong Buy
- Analyst Count
- BOSC 0
- NXTC 2
- Target Price
- BOSC N/A
- NXTC $25.50
- AVG Volume (30 Days)
- BOSC 100.6K
- NXTC 81.2K
- Earning Date
- BOSC 11-25-2025
- NXTC 11-04-2025
- Dividend Yield
- BOSC N/A
- NXTC N/A
- EPS Growth
- BOSC 55.92
- NXTC N/A
- EPS
- BOSC 0.52
- NXTC N/A
- Revenue
- BOSC $46,768,000.00
- NXTC N/A
- Revenue This Year
- BOSC N/A
- NXTC N/A
- Revenue Next Year
- BOSC N/A
- NXTC N/A
- P/E Ratio
- BOSC $10.67
- NXTC N/A
- Revenue Growth
- BOSC 15.66
- NXTC N/A
- 52 Week Low
- BOSC $2.50
- NXTC $2.69
- 52 Week High
- BOSC $5.50
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- BOSC 75.29
- NXTC 64.20
- Support Level
- BOSC $4.88
- NXTC $8.51
- Resistance Level
- BOSC $5.05
- NXTC $9.84
- Average True Range (ATR)
- BOSC 0.21
- NXTC 1.41
- MACD
- BOSC 0.05
- NXTC 0.12
- Stochastic Oscillator
- BOSC 100.00
- NXTC 59.37
About BOSC B.O.S. Better Online Solutions
BOS Better Online Solutions Ltd is a provider of Intelligent Robotics and Supply Chain solutions for enterprises. The company manages its business in three reportable divisions: the Intelligent Robotics segment, the RFID Division segment, and the Supply Chain Solutions segment. The majority of revenue derives from Supply Chain Solutions which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their components-supply needs. Geographically company derives the majority of its revenue from Israel.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.